Retinal Pigment
Signs and Symptoms
Retina360: Advances in the Treatment of Geographic Atrophy and Retinal Vein Occlusion
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Retina360: Advances in the Management of Neovascular AMD and Sustained Drug Delivery for Retinal Diseases
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
In Case You Missed: The Promise of Tyrosine Kinase Inhibitors in the Treatment of Retinal Disease
This activity is supported by an educational grant from Ocular Therapeutix, Inc.
Bleb placement change for subretinal gene therapy may prevent guttering
WAILEA, Hawaii — Retinal pigmentary changes were seen in 67% of patients in the phase 1/2 safety study of RGX-314, a gene therapy delivered subretinally for the treatment of AMD.
Iatrogenic uveitis management depends on underlying cause
WAILEA, Hawaii — Sometimes intraocular surgery itself results in some manifestation of uveitis, for which there is no clear definition in the literature, Yashi S. Modi, MD, said at Hawaiian Eye.